Your browser doesn't support javascript.
loading
Throat spray formulated with virucidal pharmaceutical excipients as an effective early prophylactic or treatment strategy against pharyngitis post-exposure to SARS-CoV-2.
Boseila, Amira A; Ghareeb, Ahmed Z; AbdElwahab, Miral G; Seadawy, Mohamed G; Al-Karmalawy, Ahmed A; Yassa, Nashwa W; Ghareeb, Doaa A.
Afiliação
  • Boseila AA; Department of Pharmaceutics, Egyptian Drug Authority Formerly Known as National Organization for Drug Control and Research (NODCAR), Giza, Egypt; Department of Pharmaceutics and Industrial Pharmacy, Faculty of Pharmacy, Sinai University, Kantara branch, Sinai 41636, Egypt. Electronic address: amira.
  • Ghareeb AZ; Center of Excellence for Drug Preclinical Studies (CE-DPS), Pharmaceutical and Fermentation Industry Development Center, City of Scientific Research & Technological Applications, New Borg El Arab, Alexandria, Egypt. Electronic address: ahmed.zaki.ghareeb@gmail.com.
  • AbdElwahab MG; Center of Excellence for Drug Preclinical Studies (CE-DPS), Pharmaceutical and Fermentation Industry Development Center, City of Scientific Research & Technological Applications, New Borg El Arab, Alexandria, Egypt; Faculty of Technological Industry and Energy, Thebes Technological University, T
  • Seadawy MG; Biological prevention department, Ministry of defense, Egypt. Electronic address: biologist202054@yahoo.com.
  • Al-Karmalawy AA; Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Horus University-Egypt, New Damietta 34518, Egypt; Pharmaceutical Chemistry Department, Faculty of Pharmacy, Ahram Canadian University, 6th of October City, Giza 12566, Egypt. Electronic address: akarmalawy@horus.edu.eg.
  • Yassa NW; Bio­Screening and Preclinical Trial Lab, Biochemistry Department, Faculty of Science, Alexandria University, Alexandria 21511, Egypt. Electronic address: nashwa_yassa@yahoo.com.
  • Ghareeb DA; Center of Excellence for Drug Preclinical Studies (CE-DPS), Pharmaceutical and Fermentation Industry Development Center, City of Scientific Research & Technological Applications, New Borg El Arab, Alexandria, Egypt; Bio­Screening and Preclinical Trial Lab, Biochemistry Department, Faculty of Sci
Eur J Pharm Biopharm ; 199: 114279, 2024 Jun.
Article em En | MEDLINE | ID: mdl-38588829
ABSTRACT
Our study aimed to develop a virucidal throat spray using bioactive compounds and excipients, focusing on the preparation of Curcumin (CUR) in a self-nano emulsifying drug delivery system (SNEDDS). Two molecular docking studies against SARS-CoV-2 targets guided the selection of proper oil, surfactant, co-surfactant, and natural bioactive that would maximize the antiviral activity of the throat spray. Two self-nanoemulsifying formulas that were diluted with different vehicles to prepare eight CUR-loaded SNESNS (self-nanoemulsifying self-nanosuspension) formulas. In vitro characterization studies and in vitro anti-SARS-CoV-2 effect revealed that the optimal formula, consisted of 20 % Anise oil, 70 % Tween 80, 10 % PEG 400, and 0.1 %w/w CUR, diluted with DEAE-Dx. Preclinical toxicity tests on male rats confirmed the safety of a mild throat spray dose (5 µg/mL CUR). In a rat model of acute pharyngitis induced by ammonia, post-treatment with the optimal formula of CUR loaded SNESNS for one week significantly reduced elevated proinflammatory markers (TNF-α, IL6, MCP1, and IL8). In conclusion, our CUR-loaded SNESNS formula, at 5 µg/mL concentration, shows promising effect as a prophylactic throat spray against SARS-CoV-2 and as a treatment for pharyngitis.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Antivirais / Faringite / Excipientes / SARS-CoV-2 / COVID-19 / Tratamento Farmacológico da COVID-19 Limite: Animals / Humans / Male Idioma: En Revista: Eur J Pharm Biopharm Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Antivirais / Faringite / Excipientes / SARS-CoV-2 / COVID-19 / Tratamento Farmacológico da COVID-19 Limite: Animals / Humans / Male Idioma: En Revista: Eur J Pharm Biopharm Ano de publicação: 2024 Tipo de documento: Article